Clinical Impact of New Rheumatoid Arthritis Findings From ACR/ARP 2020*

Download All
November 5-9, 2020; Virtual Meeting
Review the latest RA management data with Capsule Summaries and expert-authored commentaries covering key studies from ACR/ARP 2020.
Maria Danila, MD, MSc, MSPH
Jonathan Kay, MD
William F. C. Rigby, MD

Highlights

Two key studies from ACR/ARP 2020 shed new light on our use of IL-6 inhibitors, including tocilizumab and sarilumab.

William F. C. Rigby, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 4, 2020 Expired: December 3, 2021

Two key studies from ACR/ARP 2020 shed new light on the best approach to tapering therapy during RA remission.

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

New studies from ACR/ARP 2020 add to our understanding of cardiovascular safety with several RA therapeutics and demonstrate effectiveness of herpes zoster vaccination in patients with RA.

Maria Danila, MD, MSc, MSPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021

When is a rheumatoid really a rheumatoid, and what are the implications for telemedicine?

Jonathan Kay, MD William F. C. Rigby, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: December 18, 2020 Expired: December 17, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Gilead Sciences, Inc.
Sanofi Genzyme Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue